Radiation Free Study
Recruiting now · Not applicable
Conditions studied: Aortic Aneurysm
In brief
This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable. Primary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)
Key facts
- Study ID
- NCT06549348
- Run by
- Philips Clinical & Medical Affairs Global
- People needed
- 182
- Starts
- 2025-07-03
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2026-06-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject will be undergoing a primary Fenestrated Endovascular Aortic Repair (FEVAR) procedure (including subjects with prior infrarenal EVAR or open repair) that includes the incorporation of visceral arteries into the repair.
- Subject is able to give informed consent and is 18 years of age or older, or of legal age to give informed consent per state or national law.
- Subject has a life expectancy of at least 2 years
- Target vessels to be included are the Celiac Trunk, Superior Mesenteric Artery and Renal Arteries
You may not qualify if…
- Subjects undergoing an endovascular procedure that include branches or iliac branched devices (IBD) in the repair
- Subject treated for re-intervention / staged procedure post-primary FEVAR procedure
- Subjects intended to be treated for more than 4 target vessels (not counting the contralateral gate)
- Subject treated for an emergent (<24hrs after emergence) procedure
- Subject with connective tissue disorder eg, Marfan's or Ehlers Danlos Syndrome
- Subject with contrast allergies
- Subject participates in a potentially confounding drug or device trial during the course of the study. Co-enrollment in concurrent trials may be allowed provided that pre-approval is obtained from Philips.
- All vulnerable subjects such as immuno-compromised subjects, subjects lacking the capacity to provide consent, patients in emergency situations, pregnant or breast-feeding women, or any other subject who meets an exclusion criteria, according to applicable national laws, if any.
- Subject unwilling or unable to comply with the protocol unable to understand verbal and/or written informed consent
Where it is running
- Guys & St Thomas — London, United Kingdom (enrolling)
- Hôpital Universitaire Pitié-Salpêtrière — Paris, France (enrolling)
- UMC Maastricht — Maastricht, Netherlands (enrolling)
- University of Alabama — Birmingham, Alabama, United States (enrolling)
- University of Massachusetts — Worcester, Massachusetts, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- UZ Gent — Ghent, Belgium (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Rigshospitalet University Hospital — Copenhagen, Denmark
- University Medical Center Utrecht — Utrecht, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.